Blue Jet Healthcare Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r4fohthor5o7je41sjr80ken.pdf

Key Takeaways


Revenue & Segment Performance

V.K. Singh: "I do not think it is right to say that there has been a lot of volatility for the previous several quarters. I would say for the last three to four quarters, there has been sequential ramp-up."

Margins & Raw Material Headwinds

Ganesh Karuppannan: "This West Asia crisis has resulted in increase in raw material price across board. Not only raw materials, you can take any reagent, any solvent, everything has gone up. ... when it comes to reagents and solvent, you cannot actually pass on 100% of the price increase."

Capacity Expansion & R&D Build-Out

Shiven Arora: "Our ambition is not simply to add manufacturing capacity. We are building a globally competitive CDMO platform that combines decades of complex chemistry expertise with integrated R&D, flexible manufacturing infrastructure, and long-standing relationships with global pharmaceutical innovators."

Innovator-Led Pipeline & New Molecules

V.K. Singh: "That the final API will be a better opportunity than intermediates is not always true. ... If our customers want, we will be more than happy to forward integrate from the intermediates and fragments and peptide side also, and go more and more towards the finished product, maybe including the final peptide, for which we will build and have capability and capacity."

Vizag & Sweeteners

V.K. Singh: "Very few people, particularly none in India, make that. We are very confident that since it is an adjacency, it will go to our existing clients. We do not have to discover any new market. We are very confident that the capacities that we set up will get engaged very quickly with a very low gestation."

Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin recoveryPrice increases with select customers come into force; positive impact expected, net effect depends on input prices and mixFrom Q3 FY27 (positive impact expected in coming quarters)
Mahad Unit 3 on streamFacility for strategically critical KSM in contrast media businessH2 FY27
QIP deploymentPhased over three years for capex, working capital, and general corporate purposeOver next 3 years
Vizag Phase I lateral entriesMain bulk of volumes to come when Vizag is on stream"Some time away" (no date)
Clinical-stage molecules launchTwo molecules in clinical phases to reach commercial stage"Will take a while" (no date)

Key Metrics

MetricQ2 FY27
Revenue from operations₹375 cr, +28% QoQ; highest-ever quarterly revenue
EBITDA₹119 cr, 32% of operating revenue, -1 ppt QoQ
Profit after tax₹103 cr, 27% of total income, flat QoQ
Gross margin49%, -4 ppt QoQ; raw material price increases from West Asia crisis
H1 FY27 revenue₹669 cr, +29% YoY
H1 FY27 EBITDA₹217 cr, 32% of operating income, -2 ppt YoY
H1 FY27 PAT₹181 cr, 27% of total income, -1 ppt YoY
Contrast media revenue growth+25% QoQ
PI API revenue growth+52% QoQ
Artificial sweetener revenue growth-30% QoQ
Mahad Unit 3 capex incurred to date~₹250 cr
Vizag Phase I envisaged capex~₹1,000 cr
Hyderabad R&D scientists onboarded~50
Renewable energy share of consumption~80%
QIP raise₹800 cr, deployment phased over three years